Bupa to launch DNA-driven preventive care for breast cancer, diabetes and cardiovascular disease
Bupa is set to become the first major private medical insurer to roll out DNA-driven preventive healthcare to all eligible customers, in a move it says signals a “fundamental shift” away from treating illness and towards predicting and preventing it before symptoms emerge.
The initiative, branded “Prevention Pathways”, will see genomics-led personalised and preventive healthcare become a standard part of Bupa’s health insurance. It will use genetic testing, clinical assessments and AI-driven insights to identify individuals at heightened risk of conditions such as breast cancer, cardiovascular disease and diabetes.
Customers flagged as high risk will be offered earlier screening, tailored interventions and, in some cases, pre-emptive treatment, including preventive medication or surgery.
Bupa’s new Prevention Pathways
From 1 September 2026, Prevention Pathways for breast cancer, diabetes and cardiovascular disease will be available to all Bupa UK Insurance Consumer and SME renewing customers, and new customers after a 12-month waiting period. It will be available as an optional benefit to Corporate customers.
The insurer expects more than 200,000 customers to benefit from the programme by the end of 2027, following a genomics pilot study involving over 12,000 participants.
Customers will be guided through a connected care journey from DNA testing and genetic counselling to GP consultations, lifestyle advice, risk-reducing surgeries and aftercare.
For instance, for breast cancer, the new Bupa Prevention Pathway will combine digital triage and genetic testing to identify individuals with an elevated inherited risk of breast cancer. Patients could then be offered options such as preventative drugs like tamoxifen, or risk-reducing surgery such as mastectomy. The company estimates that this pathway alone could support more than 36,000 people over the next two years.
Meanwhile, for those at risk of cardiovascular disease or type 2 diabetes, the programme includes access to Bupa’s Weight Management service.
Dan Sullivan, Product and Proposition Director for Bupa Insurance, said: “By moving from treating illness to predicting and preventing it, we are redefining the role of healthcare. Early intervention leads to better outcomes, so being able to prevent illness before reaching crisis stage is key. This shift allows us to provide personal treatment plans for everyone and support our customers better than ever before.”
The Prevention Pathways programme is underpinned by Bupa’s new digital health platform, Blua, which uses AI models to interpret genetic and clinical data, offering personalised health insights and recommendations.
Bupa Medication Check service
Alongside its new Prevention Pathways, Bupa is also introducing a “Medication Check” service for customers taking long-term prescriptions. Using a saliva-based genetic test, the service aims to match patients with medications and dosages most suited to their genetic profile, reducing the trial-and-error approach that often characterises treatment for chronic conditions.
The insurer estimates that up to 4.2 million customers could eventually be directed towards more effective, personalised medication through the programme.
Dr Rebecca Rohrer, Clinical Innovation and Genomics Director for Bupa, said: “This is a turning point in how we think about healthcare, enabling people to be more proactive in preventing or delaying ill-health and having faster access to medication that works for them.”
The Bupa Medication Check will be available to all eligible new and renewing Consumer and SME Bupa UK Insurance customers from 1 June 2026. It is already available as an optional benefit to Corporate customers.
Chris Steele, founder and editor of myTribe Insurance Experts, said: “Bupa’s decision to add Prevention Pathways to its health insurance so that high-risk customers can access preventative care before they get any symptoms is a smart move. Early intervention can reduce long-term healthcare costs and improve outcomes, a proposition that will appeal to both patients and insurers. As genetic testing becomes more widespread, the idea of anticipating illness, rather than just reacting to it, is moving from an aspiration to reality.”
Learn more about health insurance
If you are considering taking out private health insurance you might find these articles helpful:
